πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 263 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12427148

Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

The Regents of the University of California Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421315

CLL-1 targeted immunotherapies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410259

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12398193

Targeted replacement of endogenous T cell receptors

The Regents of the University of California Β· Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12359220

Guided magnetic nanostructures for targeted and high-throughput intracellular delivery

The Regents of the University of California Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12325755

Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

The Regents of the University of California Β· Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12303602

Compositions, methods and uses for thermally stable multi-targeted antigens

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290505

Tissue factor-targeted antibody-drug conjugate

SHANGHAI MIRACOGEN INC. Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12264187

Compositions and methods for targeted therapeutic delivery to bone

Theradaptive, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12257247

Targeted degradation of VAV1

Monte Rosa Therapeutics AG Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234461

Targeted non-viral DNA insertions

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221607

Multi-targeted single entity conjugates

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209256

System for protein inactivation and recombinant phages for targeted bacterial killing, inf

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209142

SARS-CoV-2 epitope-targeted peptide immunostimulants

The United States of America as represented by the Secretary of the Army Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12195558

Targeted delivery system and methods of use therefor

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157735

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12134610

Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

CRINETICS PHARMACEUTICALS, INC. Β· Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084497

SIRP1Ξ± targeted chimeric proteins and uses thereof

Orionis Biosciences, Inc Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049464

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043833

Targeted compositions

ARBUTUS BIOPHARMA CORPORATION Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12031133

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998635

Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation

Northwestern University Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964024

B7H4-targeted antibody-drug conjugates and methods of use thereof

Mersana Therapeutics, Inc. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted